SCHEMBL5225969

SCHEMBL5225969

CC(C)(N)C(=O)NC(COCc1ccccc1)C(=O)N1CCN2C(=O)N(CC(F)(F)F)CC2(Cc2ccc(F)cc2F)C1

nearest known ligand 0.54

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 9/20 0.54
UGCG Q16739 6/20 0.42
CCKBR P32239 1/20 0.36
CYP3A4 P08684 3/20 0.35
MC4R P32245 2/20 0.35
TACR1 P25103 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5228528 0.91 GHSR (0.53) GHSRUGCGCCKBRCYP3A4MC4R
SCHEMBL5227645 0.85 GHSR (0.54) GHSRUGCGCYP3A4
SCHEMBL5226011 0.81 UGCG (0.44) GHSRUGCGCCKBRCYP3A4MC4R
SCHEMBL5226545 0.79 GHSR (0.62) GHSRUGCGCYP3A4
SCHEMBL5227517 0.79 GHSR (0.62) GHSRUGCGCYP3A4
SCHEMBL5226534 0.79 GHSR (0.53) GHSRUGCGCYP3A4
Hydrochloric Acid SCHEMBL7670267 0.79 GHSR (0.61) GHSRUGCGCYP3A4
SCHEMBL7067756 0.77 UGCG (0.43) GHSRUGCGCCKBRCYP3A4MC4R
SCHEMBL5229465 0.77 GHSR (0.58) GHSRUGCGCYP3A4TACR1
SCHEMBL5225971 0.77 GHSR (0.58) GHSRUGCGCYP3A4TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001970-B1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER (US) 2007-03-07 EP claimed
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure CARPINO PHILIP ALBERT (US) 2004-01-15 US claimed
US-20040006063-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2004-01-08 US claimed
US-20030216399-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2003-11-20 US claimed
US-20020042415-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-04-11 US claimed
US-20010041703-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2001-11-15 US claimed
EP-1001970-A1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER INC. (US) 2000-05-24 EP claimed
WO-1998058947-A1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER INC. (US) 1998-12-30 WO claimed
US-6953791-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-11 US disclosed
US-6951850-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-04 US disclosed
US-6924280-B2 Dipeptide derivatives PFIZER INC. (US) 2005-08-02 US disclosed
US-RE38524-E1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2004-06-01 US disclosed
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure CARPINO PHILIP ALBERT (US) 2004-01-15 US disclosed
US-20040006063-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2004-01-08 US disclosed
US-6525047-B2 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair PFIZER INC. 2003-02-25 US disclosed
US-6433171-B1 FOR OSTEOPOROSIS AND/OR FRAILTY, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ATTENUATING PROTEIN CATABOLIC RESPONSE AFTER A MAJOR OPERATION, REDUCING CACHEXIA AND PROTEIN LOSS PFIZER INC. 2002-08-13 US disclosed
US-6432945-B1 Dipeptide derivatives PFIZER INC. 2002-08-13 US disclosed
US-20020042415-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-04-11 US disclosed
EP-1001970-A1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER INC. (US) 2000-05-24 EP disclosed
WO-1998058947-A1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER INC. (US) 1998-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure GHSR, GHRHR, GIPR GHSR 1/4885UGCG 1722/4885CCKBR 120/4885
US-20020042415-A1 Dipeptide derivatives GIPR, GHRHR, GHSR GHSR 3/4885UGCG 2325/4885CCKBR 112/4885
US-20010041703-A1 Dipeptide derivatives GIPR, GHRHR, GHSR GHSR 3/4885UGCG 1989/4885CCKBR 100/4885
US-20040006063-A1 Dipeptide derivatives GIPR, GHRHR, GHSR GHSR 3/4885UGCG 2340/4885CCKBR 126/4885
US-20030216399-A1 Dipeptide derivatives GIPR, GHRHR, GHSR GHSR 3/4885UGCG 2325/4885CCKBR 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.